These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35950831)

  • 1. 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study).
    Daneshi N; Esmaeilzadeh A; Bahmaie N
    Eurasian J Med; 2022 Oct; 54(3):310-312. PubMed ID: 35950831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?
    Gardin C; Ferroni L; Chachques JC; Zavan B
    J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32858940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms.
    Kaffash Farkhad N; Mahmoudi A; Mahdipour E
    Regen Ther; 2022 Jun; 20():61-71. PubMed ID: 35340407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.
    Gurunathan S; Kang MH; Kim JH
    Front Immunol; 2021; 12():716407. PubMed ID: 34394121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes and COVID-19: challenges and opportunities.
    Babaei G; Zare N; Mihanfar A; Ansari MHK
    Comp Clin Path; 2022; 31(2):347-354. PubMed ID: 35039753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of Neutralizing Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by the Screening with Exosomes Expressing the Viral Spike Protein.
    Okada C; Ikeda-Ishizaka E; Ono C; Matsuura Y; Sonoda H
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):173-180. PubMed ID: 36027043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
    Cheng MP; Cau A; Lee TC; Brodie D; Slutsky A; Marshall J; Murthy S; Lee T; Singer J; Demir KK; Boyd J; Ohm H; Maslove D; Goffi A; Bogoch II; Sweet DD; Walley KR; Russell JA;
    Crit Care Med; 2021 Sep; 49(9):1558-1566. PubMed ID: 33870918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.
    Fedry J; Hurdiss DL; Wang C; Li W; Obal G; Drulyte I; Du W; Howes SC; van Kuppeveld FJM; Förster F; Bosch BJ
    Sci Adv; 2021 Jun; 7(23):. PubMed ID: 33958322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes, and the potential for exosome-based interventions against COVID-19.
    Rahmani A; Soleymani A; Almukhtar M; Behzad Moghadam K; Vaziri Z; Hosein Tabar Kashi A; Adabi Firoozjah R; Jafari Tadi M; Zolfaghari Dehkharghani M; Valadi H; Moghadamnia AA; Gasser RB; Rostami A
    Rev Med Virol; 2024 Jul; 34(4):e2562. PubMed ID: 38924213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes contribution in COVID-19 patients' treatment.
    Mazini L; Rochette L; Malka G
    J Transl Med; 2021 May; 19(1):234. PubMed ID: 34059065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19.
    Ghiasi M; Kheirandish Zarandi P; Dayani A; Salimi A; Shokri E
    Regen Ther; 2024 Dec; 27():319-328. PubMed ID: 38650667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.
    Akbari A; Rezaie J
    Stem Cell Res Ther; 2020 Aug; 11(1):356. PubMed ID: 32795359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment.
    Jasim SA; Aziz DZ; Mustafa YF; Margiana R; Al-Alwany AA; Hjazi A; Alawadi A; Yumashev A; Alsalamy A; Fenjan MN
    Pathol Res Pract; 2024 Feb; 254():155135. PubMed ID: 38295461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.
    Dauletova M; Hafsan H; Mahhengam N; Zekiy AO; Ahmadi M; Siahmansouri H
    Clin Immunol; 2021 May; 226():108712. PubMed ID: 33684527
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.